Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 8.

Brodowicz, T; Ciuleanu, T; Crawford, J; Filipits, M; Fischer, J R; Georgoulias, V; Gridelli, C; Hirsch, F R; Jassem, J; Kosmidis, P; Krzakowski, M; Manegold, C; Pujol, J L; Stahel, R; Thatcher, N; Vansteenkiste, J; Minichsdorfer, C; Zöchbauer-Müller, S; Pirker, R; Zielinski, C C (2012). Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. Annals of Oncology, 23(5):1223-1229.

Salazar, F; Molina, M A; Sanchez-Ronco, M; Moran, T; Ramirez, J L; Sanchez, J M; Stahel, R; Garrido, P; Cobo, M; Isla, D; Bertran-Alamillo, J; Massuti, B; Cardenal, F; Manegold, C; Lianes, P; Trigo, J M; Sanchez, J J; Taron, M; Rosell, R (2011). First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Lung Cancer, 72(1):84-91.

Brun, L; Ngu, L H; Keng, W T; Ch'ng, G S; Choy, Y S; Hwu, W L; Lee, W T; Willemsen, M A A P; Verbeek, M M; Wassenberg, T; Régal, L; Orcesi, S; Tonduti, D; Accorsi, P; Testard, H; Abdenur, J E; Tay, S; Allen, G F; Heales, S; Kern, I; Kato, M; Burlina, A; Manegold, C; Hoffmann, G F; Blau, N (2010). Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology, 75(1):64-71.

Reck, M; Stahel, R A; von Pawel, J; Karthaus, M; Korfee, S; Serke, M; Schuette, W H W; Eschbach, C; Fink, T H; Leschinger, M I; Manegold, C (2010). Pemetrexed in the treatment of malignant mesothelioma: Results from an expanded access program in Germany. Respiratory Medicine, 104(1):142-148.

Pirker, R; Herth, F J F; Kerr, K M; Filipits, M; Taron, M; Gandara, D; Hirsch, F R; Grunenwald, D; Popper, H; Smit, E; Dietel, M; Marchetti, A; Manegold, C; Schirmacher, P; Thomas, M; Rosell, R; Cappuzzo, F; Stahel, R (2010). Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. Journal of Thoracic Oncology, 5(10):1706-1713.

Carteni, G; Manegold, C; Martin Garcia, G; Siena, S; Zielinski, C C; Amadori, D; Liu, Y; Blatter, J; Visseren-Grul, C; Stahel, R (2009). Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer, 64(2):211-218.

Santoro, A; O'Brien, M E; Stahel, R A; Nackaerts, K; Baas, P; Karthaus, M; Eberhardt, W; Paz-Ares, L; Sundstrom, S; Liu, Y; Ripoche, V; Blatter, J; Visseren-Grul, C M; Manegold, C (2008). Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. Journal of Thoracic Oncology, 3(7):756-763.

Rosell, R; Manegold, C; Moran, T; Garrido, P; Blanco, R; Lianes, P; Stahel, R; Trigo, J M; Wei, J; Taron, M (2008). Can We Customize Chemotherapy? Individualizing Cytotoxic Regimens in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 9(Supplement):S76-S82.

This list was generated on Wed Sep 26 03:41:45 2018 CEST.